[Editor's Note: A version of this article originally appeared in Informa's In Vivo, including detail on biopharmaceutical deals in February. The top February pharma M&A by deal value was Indian biosimilars company Biocon Biologics agreement to acquire Viatris’ biosimilars business for up to $3.3bn. Also Code Biotherapeutics and Takeda signed an agreement to leverage Code Bio’s proprietary targeted 3DNA non-viral genetic medicine delivery platform to design and develop gene therapies for a liver-directed rare disease program, plus central nervous system-directed rare disease programs.]
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?